Oxazolidinone antibiotics such as linezolid have shown significant therapeutic effects in patients with extensively drug-resistant (XDR) tuberculosis (TB) despite modest effects in rodents and no demonstrable early bactericidal activity in human phase 2 trials. We show that monotherapy with either linezolid or AZD5847, a second-generation oxazolidinone, reduced bacterial load at necropsy in Mycobacterium tuberculosis-infected cynomolgus macaques with active TB. This effect coincided with a decline in 2-deoxy-2-[ 18 F]-fluoro-D-glucose positron emission tomography (FDG PET) imaging avidity in the lungs of these animals and with reductions in pulmonary pathology measured by serial computed tomography (CT) scans over 2 months of monotherapy. In a parallel phase 2 clinical study of linezolid in patients infected with XDR-TB, we also collected PET/CT imaging data from subjects receiving linezolid that had been added to their failing treatment regimens. Quantitative comparisons of PET/CT imaging changes in these human subjects were similar in magnitude to those observed in macaques, demonstrating that the therapeutic effect of these oxazolidinones can be reproduced in this model of experimental chemotherapy. PET/CT imaging may be useful as an early quantitative measure of drug efficacy against TB in human patients.
INTRODUCTION
Tuberculosis (TB) is a devastating disease afflicting an estimated 8.6 million people in 2012 (1) . Even chemotherapy for drug-sensitive disease is complex, requiring 6 months of treatment with four different agents to achieve a durable cure. If patients fail first-line therapy and develop multidrug-resistant (MDR) TB, a full 2 years of chemotherapy with as many as six different agents is required (2) . Of the nearly 500,000 incident cases of MDR-TB globally, only about one-fifth were detected, and only 77,000 received treatment in 2012. Given this situation, it is unsurprising that 170,000 of the estimated 1.3 million deaths from TB in 2012 were due to MDR disease (1) . Treatment success for MDR-TB globally is estimated to be only 50%, which increases the risk for the development of extensively drug-resistant (XDR) TB where the prognosis becomes even poorer. Because of the difficulty in treating such patients, the U.S. Centers for Disease Control listed XDR-TB as one of the top five global infectious disease threats last year (3) .
One of the major difficulties in managing TB is the lengthy nature of treatment regimens, and shortening treatment duration is an important goal of many ongoing efforts. Treatment duration has been determined empirically by randomized clinical trials comparing disease relapse after treatments of different durations, often motivated primarily by results in animal models of experimental chemotherapy. Mouse models of disease have been used virtually exclusively to justify exposing patients to the risk of a shortened duration of chemotherapy (4) . The standard murine disease models, however, develop none of the characteristic pathology of TB disease such as the formation of cavities in the lungs, which in human clinical trials are strongly correlated with failure and disease relapse [reviewed in (5) ], nor lesions with caseous necrosis, which are the most common lesions in human TB. Several large phase 2 and 3 treatment shortening trials have been attempted on the basis of predictions made in murine models, with disappointing results leading to concerns regarding the predictive validity of this model (6, 7) .
The lack of advanced pathology in murine TB also affects the local environment experienced by the bacilli, and differences in this environment can affect the intrinsic drug susceptibility of the organism. In humans, there is a broad spectrum of lesions with bacteria found both extracellularly and intracellularly within many cell types, whereas in the mouse, it is primarily a disease of the pulmonary macrophages (8, 9) . In addition, murine pharmacokinetic (PK) profiles are often distinct from human profiles. Drugs are more rapidly metabolized, requiring comparisons between profiles that have different peak drug concentration and half-lives. Recently, we reported a phase 2 clinical study of linezolid (LZD) in chronically infected patients with XDR-TB (10) . The study added LZD to a failing regimen that each patient had been on for at least the previous 6 months, evaluating the effect of LZD essentially as monotherapy. LZD treatment was highly effective, with 87% of these patients ultimately having TB-free sputum cultures with a median time to conversion of 76 days of therapy. This result was surprising because LZD has only modest effects in murine models of TB, yet culture conversion rates approached those seen in standard five-drug combination regimens used to treat MDR-TB. Together, these studies suggest that murine models of disease inadequately measure the effect of this drug class in human disease.
Despite the beneficial effect of LZD reported in XDR-TB patients, long-term administration of this agent is associated with significant side effects; in our study, 82% of participants experienced clinically significant adverse events. LZD is the first in class of oxazolidinone antibiotics whose mechanism involves inhibition of bacterial protein synthesis through binding to the 50S subunit of the bacterial ribosome (11) . Some of the side effects seen with LZD are a consequence of incidental binding to the human mitochondrial ribosome (12) . Knowledge of this mechanism of toxicity has invigorated a search for new oxazolidinones with an improved safety profile. Several candidates that may offer such an advantage have been identified and are in clinical trials for TB or other indications (13, 14) . One of these second-generation LZD analogs is AZD5847, a new oxazolidinone that has comparable activity to LZD against TB, both in vitro and in macrophages (15, 16) .
We have developed TB chemotherapy models in two species of nonhuman primates to determine the efficacy of agents for treatment of both latent and active disease (17) (18) (19) . The cynomolgus macaque develops TB disease that is strikingly similar to human disease (20, 21) . Here, we show that macaques have a similarly strong therapeutic response to treatment with oxazolidinones as seen in humans in terms of reduced bacterial burden after treatment. We also report similar radiological responses in both human subjects from our previous trial (ClinicalTrials.gov no. NCT00727844) and this nonhuman primate species over time using 2-deoxy-2-[ 
RESULTS

Pharmacokinetics of LZD and AZD5847 in cynomolgus macaques
To identify the doses of LZD and AZD5847 that reproduce drug exposure in humans, PK dose-finding studies were initially conducted in uninfected cynomolgus macaques. LZD was administered by oral gavage at 5, 10, and 30 mg/kg to groups of three nonhuman primates, and blood was collected at serial time points from 0 to 36 hours post-dose. Likewise, PK profiles were obtained from groups of three nonhuman primates that received AZD5847 at 10 and 20 mg/kg by oral gavage. Relevant oral PK parameters are summarized in Table 1 and compared with human PK parameters observed either in TB patients treated with LZD (22) or in human volunteers who received AZD5847 in a phase 1 study of dose finding and tolerability (23) . These results indicated that in cynomolgus macaques, a daily dose of 30 mg/kg of LZD achieved peak plasma concentrations (C max ) and exposure [area under the curve (AUC)] comparable to those observed in TB patients (Table 1) . For AZD5847, exposure did not increase between 10 and 20 mg/kg administered as single oral doses, but the terminal half-life was significantly longer at 20 mg/kg, suggesting saturation of one or more elimination processes. Multiple 20 mg/kg dose projections based on the single-dose profile predicted an increase in exposure of 20 to 25% at steady state. Therefore, a daily dose of 20 mg/kg was selected to best reproduce C max , and exposure at one possible human dose of 400 mg twice daily (23) . (The concentration-time profiles of LZD at 30 mg/kg and AZD5847 at 10 and 20 mg/kg are presented in fig. S1 .)
To ensure that target drug concentrations were achieved in animals on treatment, blood samples were collected weekly at 6 hours post-dose during efficacy studies; that is, each animal contributed seven to eight blood samples obtained once a week during the 2-month period of daily treatment. Average LZD concentrations at 6 hours post-dose ranged from 10 to 16 mg/ml, with interweek SDs of 4.4 to 10.9 mg/ml within nonhuman primates. For AZD5847, average plasma concentrations at 6 hours ranged from 1.6 to 5.1 mg/ml, with interweek SDs of 0.9 to 3.2 mg/ml. These drug concentrations confirmed the anticipated accumulation of AZD5847 at steady state compared to single dose and were within the human-equivalent target range (Table 1) , taking into consideration interanimal and interoccasion variability in the rate and extent of absorption.
To assess the side effects of oxazolidinones, complete blood cell counts were performed on control and treated animals biweekly during treatment. Changes in white cell counts, hemoglobin, platelets, or reticulocytes were not noticeably different from controls in the subset of animals monitored (table S1).
Microbiological and pathological responses to oxazolidinone treatment in nonhuman primates Cynomolgus macaques were infected with Mycobacterium tuberculosis (Mtb) and monitored for progression to active disease, on the basis of Table 1 . Pharmacokinetics of LZD and AZD5847 in primates. Shown are pharmacokinetics data for LZD and AZD5847 in cynomolgus macaques and in humans at clinical doses (LZD) (22) or projected efficacious doses (AZD5847) (23) . C max , peak plasma concentration; T max , time to peak plasma concentration; AUC , area under the curve from 0 to 24 hours post-dose; previously published criteria (18, 21) . As with humans, macaques present with a wide range of disease severity. Nonhuman primates with active disease were subjected to a baseline PET/CT scan and randomly assigned to no treatment (n = 9), LZD (30 mg/kg per day, n = 5), or AZD5847 (20 mg/kg per day, n = 6) groups and treated once daily for 2 months, after which the animals were humanely euthanized. Prenecropsy PET/ CT scans were used as maps for obtaining individual tracked lesions, thoracic lymph nodes, and other pathologies, and a pathologist blinded to the study scored the gross pathology on the basis of a published scoring system (21) . Tissue samples, including most granulomas, all thoracic lymph nodes, all lung lobes including uninvolved tissue, and extrapulmonary sites (liver and spleen), were obtained for bacterial culture and histopathology, as previously described (18) .
In previous work, we developed and validated a scoring system [colonyforming unit (CFU) score] for estimating total bacterial burden in nonhuman primates (21) , on the basis of plating of all samples described above. This CFU score reflects a quantitative assessment of all visible lesions and all lymph nodes as well as samples from an area of ostensibly healthy lung and is a reasonable estimate of total bacterial burden. We have shown in a previous work that this score successfully discriminates effectively drug-treated animals from untreated controls in the cynomolgus macaque model (18) . As expected with outbred nonhuman primates, the active TB untreated controls had a wide range of bacterial burden at necropsy. CFU scores were significantly lower in the LZDtreated and AZD5847-treated groups (P < 0.05 for AZD5847; P < 0.01 for LZD), compared to controls (Fig. 1A) . As a means of assessing the ability of these agents to sterilize infected tissues, we calculated the percentage of all samples in each monkey that were positive for Mtb; untreated nonhuman primates had a higher proportion of samples that grew Mtb compared to either LZD-treated (P < 0.01) or AZD5847-treated (P < 0.01) animals (Fig. 1B) . We also quantified bacterial burden in individual lesions by plating each individual granuloma and thoracic lymph node obtained from each animal and enumerated the actual number of bacilli per lesion. The median CFU from individual granulomas from active TB controls was significantly higher than the median CFU of individual granulomas from LZD-or AZD5847-treated animals (P < 0.001 for both; Fig. 1C ). The proportion of lesions that were sterile [that is, no culturable bacilli, as defined previously (24)] from the LZD-or AZD5847-treated animals was also significantly higher than the proportion of sterile lesions in the granulomas of untreated animals (P < 0.05 for both; Fig. 1D ). Finally, the bacterial burden in thoracic lymph nodes was significantly reduced in both the oxazolidinone-treated groups compared to that in untreated animals (P < 0.001 for AZD5847; P < 0.05 for LZD; Fig. 1E ). These data suggest that, as a single-drug therapy, both oxazolidinones are capable of reducing overall bacterial burden and sterilizing individual granulomas within 2 months of treatment.
CT responses in LZD-or AZD-treated nonhuman primates Animals received PET/CT scans immediately before the initiation of chemotherapy and after 4 or 8 weeks of treatment, with 8 weeks being . P values are indicated as follows: *P < 0.05, **P < 0.01, and ***P < 0.001, where a Bonferroni correction has been applied to the P values to account for the two comparisons (AZD versus control; LZD versus control). Short horizontal black lines indicate median. n.s., not significant. One control macaque was excluded from bacterial burden analyses due to culture contamination.
immediately before necropsy. All three scans for each animal were carefully co-registered, focusing on maximizing alignment of disease sites. ROIs were then manually delineated in the thoracic cavity on all three scans simultaneously, excluding lymph nodes, and the total diseaseassociated abnormal volume was computed. As with human TB patients, the macaques presented with a variable extent of disease ranging from <1 to 24 ml of volume between −500 and 200 Hounsfield units [HU, a quantitative measure of radiodensity referenced to water (0) and air (−1000)]. On the basis of the correlation of reader scores observed in human CT scans (25) , we analyzed these densities in two separate windows, a "soft" window between −500 and −100 HU that correlated more with nodular lesions and opacities and a "hard" window from −100 to +200 HU corresponding to consolidative features and cavity walls. For each subsequent scan, we enumerated the log 2 fold change in voxels of that density compared to the baseline volume.
Control animals primarily showed evidence of progressive disease in both windows, whereas both treatment groups showed evidence of response to therapy at 1 month that increased in extent at 2 months ( Fig. 2A and fig. S2 ). Although most of disease (75 to 80%) was associated with "soft" lesion density, the resolution of hard features appeared more rapid and consistent. Both groups of treated animals showed quantitative reductions in disease density at a similar rate, suggesting roughly equal efficacy of these two agents in this model.
PET responses to LZD or AZD treatment in nonhuman primates
FDG uptake was quantified in co-registered scans from the entire thoracic cavity and enumerated as total activity for each animal. As with CT abnormalities, a wide range of initial uptake was observed in these scans, and untreated animals had a tendency either to remain unchanged in their total uptake of FDG or to show an increase, sometimes substantially (half of the untreated animals experienced more than a 50% increase in total activity over the 2-month period) ( Fig. 2B; fig. S3 shows examples of scans from individual animals on treatment). In contrast, treated animals exhibited mostly consistent reductions in FDG uptake. Combining all the data from these animals, the total activity was reduced by 2 months in oxazolidinone-treated animals, whereas an increase in total activity was observed in untreated nonhuman primates (Fig. 5) . There was a significant reduction in total activity in both LZD-and AZD-treated animals as early as 1 month after starting treatment (P < 0.05).
Dynamic PET changes in untreated patients with XDR-TB As a substudy within our phase 2 clinical trial of the use of LZD in treating subjects with chronic, nonresponsive XDR-TB (10), we included subjects who were healthy enough to participate in an evaluation of the timing of PET/CT scanning to monitor their response to treatment with LZD. Nineteen of 41 subjects enrolled in the study consented to participate in this substudy (one subject was withdrawn after the baseline scan because s/he did not have XDR-TB). All subjects in the substudy received baseline scans immediately before receiving LZD as well as scans after receiving 6 months of LZD. All subjects also were randomly assigned to receive an additional scan at (i) 2 months before starting LZD (delayed arm only, n = 5); (ii) 1 month after starting LZD (n = 4); (iii) 2 months after starting LZD (n = 4); or (iv) 3 months after starting LZD (n = 5). According to this schedule, each substudy subject received a total of three scans up until 6 months of LZD treatment.
Five subjects enrolled in the delayed therapy arm of the main study received PET/CT scans upon enrollment and then immediately before receiving their first dose of study drug. Of these five, three showed slight increases in total activity summed across their entire lungs on their second scan, whereas two stayed stable. Analysis of the lesions in these subjects, however, revealed changes in FDG uptake by individual lesions as illustrated by the example from one individual shown in Fig.  3A . This subject had a 10-year history of disease, and his bacterial isolate was resistant to every available therapy, but he had been maintained on isoniazid and levofloxacin for the 6 months before study entry and experienced no change in his failing regimen for the first 2 months per study protocol. Nonetheless, this subject developed a new left lower lobe lesion near the heart, whereas a middle lobe lesion near the mediastinum resolved. Over the same period, his sputum smear went from 2+ to 3+ on the internationally accepted standard semiquantitative scale for grading the number of acid-fast bacilli present. The days to positivity of his BACTEC culture (an automated culture system widely used in clinical mycobacteriology) went from 28 to 15, consistent with a slight worsening of disease. This general pattern of local waxing and waning of lesions was observed in all five patients in this group ( fig. S4 shows scans for the other four patients). Patients in this subgroup with an extensive and long history of disease showed evidence of both regressing and progressing lesions, new lesions, and newly infected lymph nodes in this short 2-month interval before being treated with LZD. This level of dynamic change in individual lesions, against a backdrop of relatively constant overall disease in the lung, highlights the dynamic and local nature of TB lesions, similar to our data in macaques (21, 24) .
PET changes in LZD-treated subjects
Upon starting LZD therapy, all but two subjects showed a consistent diminution of total activity in their lungs by 6 months as shown in Fig. 3B . Two other subjects had a transient increase in total activity at the intermediate scan time point (one at month 1 and the other at month 2). An example of this rapid response to therapy is shown in Fig. 3A (compare the middle pre-LZD scan to the right scan at 6 months). A single subject showed a decrease in total activity at 1 month followed by a doubling of FDG uptake at 6 months. Examination of the microbiological response of this patient showed an initial improvement over the first 2 months in both smear and culture, but by month 4 of treatment, both had become positive again, and the minimum inhibitory concentration for LZD of bacilli isolated from his sputum went from 0.5 mg/ml at 12 weeks to 4 mg/ml at 21 weeks. Sequencing of the 23S ribosomal RNA gene from this patient's 21-week sputum Mtb isolate revealed a mixture of the wild-type allele (G2576) and a mutant allele (G2576T). Sequencing of a sputum sample obtained at 53 weeks revealed only the mutant allele. Examination of this patient's entry scan showed bilateral apical disease, including a large cavity in the left upper lobe, which was the major site of metabolically active disease (Fig. 4) . This cavity partially resolved at 1 month (Fig. 4, lower left) , but on the 6-month (24-week) scan, a new anterior lesion appeared from the bottom of the initial cavity ( Fig. 4 ; lower right shows the new lesion in red; fig. S5 shows additional detail). This is therefore the likely site of expansion of the LZD-resistant Fig. 3 . Radiological response rates for subjects in the LZD substudy. (A) Representative subject in the delayed arm, who was enrolled after failing all available therapy and monitored for 2 months before receiving LZD treatment. FDG PET scans were taken at study entry (left), immediately before receiving LZD (center), and after 6 months of LZD therapy (right). All scans are shown projected at the same standardized uptake value (SUV). The green arrow shows a lesion that spontaneously resolved during the two months in which this subject was on the delayed arm prior to receiving LZD and the yellow arrow shows a new lesion that appears in the same time interval. This subject finished 2 years of LZD therapy and was disease-free at the follow-up visit 6 months after discontinuing therapy. (B) Temporal responses of individual subjects during LZD therapy. Individual subjects received three scans in total and were randomly allocated to different scanning times. "−2" refers to subjects enrolled in the delayed start arm who received a study entry exam but had no change to their failing regimen and also received a second scan immediately before the start of therapy. "0" (on the x axis) refers to the scan collected before administration of LZD (up to 1 week before drug start). Scans were collected within a 2-week period of the indicated time point. P = 0.009 for the difference in mean total activity between month 0 and month 6. bacteria. (Figure S6 shows PET and CT changes for the four LZD XDR-TB patients with PET/CT scans at 2 months relative to the PET/CT changes for the MDR-TB patients in the companion paper.)
Comparative PET changes with oxazolidinone treatment across humans and nonhuman primates Averaging total activity log 2 fold changes from baseline to posttreatment time points across all human subjects who received scans at 1, 2, and 3 months showed an overall response by 3 months (Fig. 5) , allowing direct comparisons of the response magnitude to that observed in the macaques. The magnitude of the response seen in this nonhuman primate species to treatment with LZD was quantitatively similar to the response observed in human subjects (compare the dotted blue and solid blue lines in Fig. 5 ). The changes in CT volumes in these chronically infected subjects across the first 3 months were minimal; many of these subjects had extensive areas of FDG-cold but CT dense lesions that presumably reflected pathology from previously treated or less active areas of disease, highlighting the use of measuring metabolic activity ( fig. S7, A and B) .
DISCUSSION
LZD and AZD5847 appear to elicit similar therapeutic responses in nonhuman primates as measured by both bacteriological burden at necropsy and radiological endpoints. This result stands at odds with reports in the literature that AZD5847 results in a substantially higher rate of killing of bacilli (1.5 log 10 CFU/ml after 10 days) than LZD (<0.5 log 10 CFU/ml after 10 days) in infected murine bone marrow-derived macrophages with a similar disparity seen in aerobic killing of Mtb (15) . This differential sensitivity is not unexpected because Mtb in primates (human or nonhuman) is neither found exclusively within macrophages nor growing on rich medium containing glucose and glycerol (9) . It does, however, reinforce the importance of exploring models of experimental chemotherapy that more faithfully recapitulate the physiological state(s) of the bacterium and complex pathologies in humans when making predictions regarding their likely use in the clinic.
These results support further clinical evaluation of AZD5847 because the efficacy of LZD in TB patients appears good (26) (27) (28) (29) . Because the primary concerns with wider usage of LZD revolve around safety issues, this newer oxazolidinone may well show fewer side effects. Future studies with AZD5847 should therefore focus on establishing the longterm safety of administration of this agent in TB patients.
This study was designed to allow a direct comparison of radiological changes in human patients and nonhuman primates being treated effectively with oxazolidinone monotherapy. Human subjects recruited into this study were required to have a history of a stable, unchanging, and failing regimen for the prior 6 months. At the time of LZD addition, no changes to this failing regimen were allowed per protocol. Changes were allowed after sputum smear conversion, on the basis of the results of comprehensive drug susceptibility testing performed on their initial isolates. During the first 2 months of therapy, when PET/CT data for comparison were collected, no additional regimen changes were made; thus, the changes in radiological features were likely to be due solely to the addition of LZD.
Although the subjects included in this study had experienced multiple rounds of failed chemotherapy, in general the extent of lung pathology is similar to primary disease albeit on the more severe end of the spectrum. PET reports on active areas of disease, which offers a significant benefit over structural imaging modalities like chest x-rays or CT in that it allows discrimination between active sites of disease and residual pathology from disease that has resolved. Although the small numbers of patients reported herein are a limitation, the fact that response rates by PET can be observed and quantified suggests that this imaging modality is an important adjunct to microbiological response rates that may improve the precision of early phase 2 evaluations of new drugs and regimens. Our results corroborate the results reported in our companion paper (25) . In that study, 28 subjects with pulmonary MDR-TB were treated with an optimized regimen for 24 months and then followed another 6 months for final treatment outcomes. PET/CT scans were conducted at baseline and at 2 and 6 months, and quantitative changes were correlated with final treatment outcomes at 30 months. The magnitude of PET/CT changes in the four LZD-treated subjects at 2 months was consistent with the decreased FDG avidity reported in that Fig. 4 . CT findings of a patient showing an initial response to therapy followed by emergence of LZD resistance. This subject presented with bilateral, apical disease with the major site of FDG avidity being the left upper lung (yellow; see fig. S5 ). At 1 month (left bottom shows the isolated left lung), this site of disease showed a modest reduction in metabolic activity and a slight resolution of CT features consistent with a positive response to therapy. At 6 months (bottom right), a new lesion (red) emerged anterior and inferior to the initial large apical cavity in the left upper lobe. Initially, the patient's sputum smear and culture converted to negative, but subsequently, the patient developed LZD-resistant bacteria; this was confirmed genetically to map to the LZD binding site. study. However, these changes were less marked than the changes seen in our companion study ( fig. S6) (25) . This is not surprising because the LZD-treated subjects had XDR-TB and effectively received only one active drug, whereas the companion study patients had MDR-TB and received an optimized regimen with four to five active drugs.
The correspondence in magnitude and timing of the PET/CT responses seen in these subjects was similar to the magnitude and the timing observed in oxazolidinone-treated cynomolgus macaques (Fig. 5  and fig. S7, A and B) , suggesting that, at least for this class of agent, this model is likely to have predictive validity for human therapeutic use. The PET/CT data in macaques are validated by measures of bacterial burden. In the nonhuman primates, the total activity correlates reasonably well with lung bacteriological burden ( fig. S8) , which is consistent with the human response data. Thus, our data support that PET/CT imaging can be used to rapidly assess therapeutic response, with the added benefit that single-drug treatment is acceptable in animal models, whereas it is not in most human studies. PET/CT offers a valuable bridging tool between animal models and early-phase human clinical trials, and the nonhuman primate model presents a tractable alternative to explore combination studies with new and existing agents as well as studies of appropriate treatment duration, before exposing human subjects to additional risk.
Lastly, our study highlights the dynamic nature of individual lesions in patients with a long-standing history of disease, revealed by scanning subjects in the delayed arm, at study entry, and immediately before their first dose of LZD. In untreated subjects, this response was highly asynchronous: individual lesions progressed and regressed without anymajor consistent changes across all lesions. This suggests that the fate of an individual lesion in patients with active disease (without strong drug pressure) is determined locally, and that TB disease, rather than a chronic set of stable lesions, may in fact be much more heterogeneous than initially supposed. This heterogeneity may explain the paradox of the well-documented impact of isoniazid on patients with latent disease despite the complete lack of impact of isoniazid on nonreplicating bacilli (30) . Isoniazid may simply tip the balance by blocking the development of new lesions, whereas existing lesions cycle through a natural waning that favors the host. We have argued that latent TB infections, in particular, represent a metastable spectrum ranging from sterile lesions to subclinical disease (31) , and these results fit with a dynamic and heterogeneous picture of both latent and active disease. The cynomolgus macaque model faithfully reproduces this heterogeneity. Using the quantitative PET/CT imaging measures described in these studies provides a translatable means of measuring drug efficacy in human clinical trials.
MATERIALS AND METHODS
Study design
Cynomolgus macaques (Macacca fasicularis) were infected with M. tuberculosis (strain Erdman) via bronchoscope and monitored clinically, as previously described (21, 24) . Upon development of active TB, animals were randomly assigned to one of three groups: untreated, LZD, or AZD5847. Animals were followed for 2 months of treatment and then necropsied. Gross pathology, overall bacterial burden scores, and individual granuloma and thoracic lymph node CFU were calculated as described (21, 24) for treatment response. PET/CT scans were performed at baseline (randomization) and at 1 and 2 months of treatment. Samples were obtained for analyses using the prenecropsy PET/CT scan as a road map, as previously described (24) . 
PET/CT scan analysis
Humans. The human LZD study PET/CT scans were done as a substudy of a previously published larger trial (10) and were analyzed by one reader using MIM software (v. 6.1, MIM Software Inc.). For each patient, individual PET/CT scans were fused together, then co-registered across three time points (−2, 0, and 6 months; 0, 1, and 6 months; 0, 2, and 6 months; or 0, 3, and 6 months). To improve further the alignment of the lungs, the first and second scans were each deformed to the third scan. With the Region Grow tool, a region of interest (ROI) was drawn around the entire lung, which was automatically propagated to all three scans. The ROI was manually refined to include all pulmonary lesions while excluding extrapulmonary structures, including the ribs, mediastinum, and heart. When the scans were not perfectly aligned, extrapulmonary structures were excluded from all scans even if this meant excluding some pulmonary areas in other scans. Once the ROI was drawn, it was contracted by 0.2 cm to ensure that all extrapulmonary structures were excluded. This contracted ROI was then used for all subsequent calculations. HU and SUV histograms were exported for the contracted ROI at each time point. The HU histograms were analyzed using HU −500 to −100 range to represent "soft" lesions and −100 to +200 range to represent "hard" lesions. To exclude background PET uptake, total activity for SUV ≥2 was calculated by exporting histograms of ROIs according to SUV values and calculating the product of the fractional proportion and the SUV value, the aggregate sum of which was then multiplied by the ROI volume to generate the total activity.
Macaques. PET/CT scan was performed using a microPET Focus 220 preclinical PET scanner (Siemens Medical Solutions) and clinical eight-slice helical CT scanner (Neurologica Corp.) as previously described (18) . Serial macaque PET/CT scans were performed at baseline and 1 and 2 months after treatment was initiated. OsiriX viewer, an open-source PACS (picture archiving and communication system) workstation and DICOM (Digital Imaging and Communications in Medicine) image viewer, was used for both human and macaque scans analyses. Considering the variable amount of baseline disease in both the human TB patient and macaque scans, the following methods were used to quantify areas of FDG-avid pathology only and exclude uninvolved lung. A whole thoracic cavity ROI was segmented with a threshold of normal lung HUs (<−200 HU) on CT using a growing region algorithm in the OsiriX viewer. A closing tool was used, and the ROI was manually edited as necessary to include all thoracic cavity pathology. This ROI was transferred to the co-registered PET scan, and voxels outside the ROI were set to zero to exclude normal, uninfected FDG-avid tissue, such as the heart and vertebrae. Mediastinal lymph nodes, confirmed at necropsy, were excluded from the total activity analyses of the macaque scans. All regions of FDG-avid pathology (SUV >2.3) were manually selected with the OsiriX growing region algorithm, and the total activity was then computed as described above. Because serial PET/CT images were not co-registered, this process was repeated for each scan, and the total activity at each time point was calculated. Macaque PET analyses were normalized to resting muscle.
Statistical analyses
Primary analyses focused on comparisons of AZD and LZD versus control, using the Wilcoxon rank sum statistic to test for significance and a Bonferroni correction. Additional tests were similarly based on nonparametric tests. Significance of clustered data, such as that arising from multiple CFU counts per subject, was determined using the bootstrap method (32) . Comparisons of longitudinal results were evaluated using permutation-based P values to ensure appropriate family-wise error rates given the multiple hypothesis tests. Statistical analysis was conducted using R version 3.1.1.
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